LIBRETTO-531
Showed that a drug built specifically for the RET mutation beats the older multi-target pills in medullary thyroid cancer, with far fewer side effects.
PFS HR 0.28 (12-month PFS 86.8% vs 65.7%); treatment failure-free survival HR 0.25; grade ≥3 adverse events 52.8% vs 76.4%. NEJM 2023. First randomised proof that RET-selective therapy should be first line.
- 86.8 vs 65.7 out of 100 alive without the cancer growing at 12 months with Selpercatinib compared with Cabozantinib or vandetanib; 21.1 more per 100.
- Roughly one extra person helped for every 5 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 72 percent lower chance of the event at any given time (hazard ratio 0.28).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Untreated progressive RET-mutant medullary thyroid cancer: selpercatinib vs cabozantinib or vandetanib. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (RET); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
291 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival at 12 monthsprimary | Selpercatinib | — | 86.8% | 0.28 | — | link |
| Cabozantinib or vandetanib | — | 65.7% |
Pages like this
not linked directly; found by shared links- ProductPralsetinib
Shares Selpercatinib, RET, Thyroid cancer, Small-molecule kinase inhibitors.
- PersonAlexander Drilon
Shares Selpercatinib, RET, Thyroid cancer, Small-molecule kinase inhibitors.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares LIBRETTO-431, Selpercatinib, RET, Small-molecule kinase inhibitors.
- TrialARROW (thyroid cohorts)
Shares RET, Thyroid cancer, Small-molecule kinase inhibitors.
- TrialSELECT
Shares RET, Thyroid cancer, Small-molecule kinase inhibitors.
- PersonKoichi Goto
Shares Selpercatinib, RET.
- TrialDECISION
- TrialASTRA